NCT05868382View on ClinicalTrials.gov

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Influenza
Interventions
BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

mRNA-1010.4

Sterile liquid for injection

BIOLOGICAL

mRNA-1010.6

Sterile liquid for injection

Trial Locations (10)

13905

United Medical Associates, Binghamton

20854

Rockville Internal Medicine, Rockville

33024

CenExel RCA, Hollywood

33135

Suncoast Research Group, Miami

48076

DM Clinical Research, Southfield

66219

Johnson County Clin-Trials, Lenexa

68510

Meridian Clinical Research, Lincoln

68901

Meridian Clinical Research, Hastings

77375

Texas Center for Drug Development, Tomball

77478

DM Clinical Research, Sugar Land

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT05868382 - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults | Biotech Hunter | Biotech Hunter